Arvinas’ cancer drug candidates demonstrate favourable profile in Phase I trials. Credit: skeeze from Pixabay.

US-based biotechnology firm Arvinas has reported positive data from the ongoing Phase I clinical trials of its cancer drug candidates, ARV-110 and ARV-471.

Based on the company’s PROTAC platform, ARV-110 and ARV-471 are protein degrader products that target the androgen receptor (AR) and the oestrogen receptor (ER), respectively.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The open-label, dose-escalation Phase I trials of the drug candidates are designed to assess safety, tolerability and pharmacokinetics, along with anti-tumour activity and pharmacodynamics.

ARV-110’s study involves 28-36 metastatic castration-resistant prostate cancer (mCRPC) patients who have progressed on a minimum of two previous systemic therapies.

The trial assessing ARV-471 will enrol 24-36 participants suffering from oestrogen receptor-positive (ER+) / human epidermal growth factor receptor-2 negative (HER2-) locally advanced or metastatic breast cancer.

ARV-471 will be tested in patients who had prior hormonal therapy and chemotherapy.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Initial trial results indicated that both the drugs are well tolerated across the doses evaluated, without any dose-limiting toxicities (DLTs) or grade 2, 3, or 4 adverse events.

ARV-110 data is from the first three dose-escalation cohorts assessing 35mg, 70mg and 140mg doses. The company also reported dose-proportional exposures of the drug.

For ARV-471, the results are from three patients in the 30mg dose cohort.

Arvinas CEO John Houston said: “We are seeing a favourable overall safety profile for both clinical programs to date, and dose-proportional exposures of ARV-110.

“We are encouraged by these initial results as we work to create well-tolerated therapies to treat serious diseases.”

The company will increase the dose of ARV-110 to 280mg and that of ARV-471 to 60mg in the next cohorts. Additional data from the Phase I trials is expected to be available next year.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact